Norris Perne & French LLP MI held its position in Novo Nordisk A/S (NYSE:NVO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 35,545 shares of the company’s stock at the end of the second quarter. Norris Perne & French LLP MI’s holdings in Novo Nordisk A/S were worth $1,525,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of NVO. Proficio Capital Partners LLC boosted its position in Novo Nordisk A/S by 155.6% in the first quarter. Proficio Capital Partners LLC now owns 2,472 shares of the company’s stock worth $103,000 after buying an additional 1,505 shares during the period. Tower Research Capital LLC TRC boosted its position in Novo Nordisk A/S by 167.8% in the first quarter. Tower Research Capital LLC TRC now owns 3,061 shares of the company’s stock worth $105,000 after buying an additional 1,918 shares during the period. Parallel Advisors LLC boosted its position in Novo Nordisk A/S by 120.3% in the first quarter. Parallel Advisors LLC now owns 2,844 shares of the company’s stock worth $117,000 after buying an additional 1,553 shares during the period. Advisory Services Network LLC purchased a new position in Novo Nordisk A/S during the first quarter worth $127,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in Novo Nordisk A/S by 3,609.0% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,709 shares of the company’s stock worth $127,000 after buying an additional 3,609 shares during the period. Institutional investors and hedge funds own 6.40% of the company’s stock.

Shares of Novo Nordisk A/S (NVO) opened at 42.06 on Monday. The stock has a market capitalization of $104.97 billion, a price-to-earnings ratio of 17.58 and a beta of 0.63. The stock’s 50 day moving average is $42.86 and its 200-day moving average is $38.45. Novo Nordisk A/S has a 52 week low of $30.89 and a 52 week high of $50.30.

WARNING: “Norris Perne & French LLP MI Has $1,525,000 Stake in Novo Nordisk A/S (NVO)” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/07/norris-perne-french-llp-mi-has-1525000-stake-in-novo-nordisk-as-nvo.html.

A number of research analysts have weighed in on the stock. BidaskClub upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, June 15th. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a research report on Wednesday, June 21st. Finally, TheStreet upgraded shares of Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research report on Tuesday, May 2nd. Five investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the stock. Novo Nordisk A/S currently has an average rating of “Hold” and an average target price of $53.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.